Horizon Pharma (HZNP) Enters Settlement agreement with Express Scripts (ESRX); Will Pay $65M
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Horizon Pharma plc Provides Update on PBM Formulary Status for Primary Care Medicines
September 29, 2016 8:01 AM EDTDUBLIN, Ireland, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has entered into a rebate agreement with Prime Therapeutics, which secures formulary status for its primary care medicines. The rebate agreement begins on October 1, 2016.Â
Our philosophy is and will continue to be to ensure that patients have access to the medicines their physicians prescribe, said Timothy P. Walbert, chairman, president and chief executive officer. The... More